New method for identifying proteins should have “a major impact on the development of new biologics,” U of T researcher says
Biologics are a type of drug that results from the high-tech manipulation of our own proteins, as opposed to more traditional drugs built from synthetic chemicals. Because of their success so far, scientists are racing to create new biologics – and now, a U of T researcher has developed a way to make that process more powerful.
Philip M. Kim, an associate professor in U of T’s Donnelly Centre for Cellular and Biomolecular Research, combined high-tech computer simulation and high-throughput laboratory experiments to create what he hopes will be the most effective way to discover the proteins that are key to new biologics. His research was published online in the journal Science Advances on July 20, 2016.
“A large fraction of new therapeutics these days involve engineered proteins that latch onto a drug target, for instance on a cancer cell,” says Kim, also of the departments of molecular genetics and computer science. “Finding a protein that effectively binds to a target can feel like looking for a needle in a haystack.
“Our method should open up new opportunities to find those key proteins – and make a major impact on the development of new biologics.”
Under the traditional approach to developing a biologic, researchers identify a protein of interest and then test billions of variants, either randomly generated or from a natural source, hoping to find an effective binder. But these methods allow very little control over where and how the protein performs this crucial function on its target – a major factor in its effectiveness.
Kim and his team took a different approach. They used a computer to simulate the binding process, and then designed proteins that would work on the target. This type of theoretical approach has been in development for several decades, but is still not effective enough. So Kim combined the best of both methods. Instead of randomly creating massive libraries of variants, as with the traditional approach, he used computer modelling to generate a smaller, but intelligently designed repertoire of variants. Designing each variant allows for the tight control of all its properties, in contrast to conventional approaches.
“We showed that this method gives you binders that are somewhat stronger than what you get with the conventional approach,” says Kim. “The much smaller library also solves many technical problems, and we can screen for new, previously unscreenable, targets. It’s a very exciting time for cancer research, and for biologics.”
For Kim, the next step is to produce proteins that are important to certain types of cancer, but have not been screened before due to the difficulty producing them.
Learn more: A more powerful way to develop therapeutics?
The Latest on: Biologics
via Google News
The Latest on: Biologics
- EMA Completed Pre-Approval Inspection of cGMP DS and DP Facilities for Trogarzo at WuXi Biologics on February 18, 2019 at 10:52 pm
WuXi Biologics completed EMA GMP Inspection, the first biologics company in China SHANGHAI, Feb. 19, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics ... […]
- EMA Completed Pre-Approval Inspection of cGMP DS and DP Facilities for Trogarzo(TM) at WuXi Biologics on February 18, 2019 at 4:21 pm
SHANGHAI, Feb. 18, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, ... […]
- Dr. Michael Goldsmith: How robotics and biologics are changing the spine field on February 18, 2019 at 3:28 pm
Michael Goldsmith, MD, spine surgeon at Bethesda, Md.-based The Centers for Advanced Orthopaedics and chief of orthopedics at Washington, D.C.-based Sibley Memorial Hospital, discusses spine technolog... […]
- What We're Reading: Canada Sets Biologics Naming Rules; Heath Trackers and Employee Privacy; IVF and Embryos on February 18, 2019 at 7:15 am
Health Canada announced that all biologics, including biosimilars, will be identified by their brand names and nonproprietary names without the addition of a product-specific suffix; a boom in the use ... […]
- VIDEO: ISET hot topics include biologics, vessel preparation, cost on February 16, 2019 at 5:06 am
In this video exclusive, George Adams, MD, highlights hot topics in vascular intervention at this year’s International Symposium on Endovascular Therapy, including issues surrounding biologic therapy, ... […]
- Wound Care Biologics Market Industry Insights 2019| Key Players: Smith & Nephew, Integra Life Sciences, Mölnlycke Health Care AB on February 15, 2019 at 9:36 am
Global Wound Care Biologics Market is set to exceed USD 2.5 billion By 2025; according to a new research report by Global Market Insights. Increasing geriatric population globally will surge demand fo... […]
- Biologics and Biosimilars market insights shared in detailed report on February 14, 2019 at 1:50 am
News from QY Research, Inc. This report focuses on Biologics and Biosimilars volume and value at global level, regional level and company level. From a global perspective, this report represents overa... […]
- At 3.6% CAGR, Spine Biologics Market Size is Expected to Exhibit USD 2550 million by 2024 on February 13, 2019 at 11:49 pm
Feb 14, 2019 (Heraldkeeper via COMTEX) -- The worldwide market for Spine Biologics is expected to grow at a CAGR of roughly 3.6% over the next five years, will reach 2550 million US$ in 2024, from 206... […]
- Stopping Biologics Before Joint Surgery: Is Earlier Better? on February 12, 2019 at 2:35 pm
Withholding intravenous abatacept (Orencia) for longer than a month before hip or knee arthroplasty among patients with rheumatoid arthritis (RA) did not lower the risk for postoperative infection, a ... […]
- ADMA Biologics enters into $72.5M loan facility; shares up 7% premarket on February 12, 2019 at 10:26 am
ADMA Biologics (NASDAQ:ADMA) has entered into a senior secured term loan facility with Perceptive Advisors for up to $72.5M under two funding tranches. The first tranche of $45M was used to prepay ... […]
via Bing News